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Of the 28 mAbs currently marketed in 
the European Union or the US, 26 are 
marketed in Europe and 27 are mar-
keted in the US, with 25 marketed in 
both regions (Table 1). Catumaxomab 
is approved in Europe but not the US; 
tositumomab-I131 is marketed in the 
US but not Europe. Brentuximab vedo-
tin was approved in the US in 2011 and, 
as of March 2012, a marketing applica-
tion for the mAb is undergoing review 
by the European Medicines Agency.1 Of 
the 28 mAbs that are marketed in one or 
the other region, 43% (12/28) are pro-
duced in Chinese hamster ovary (CHO) 
cells, 25% (7/28) are produced in SP2/0 
cells,2 18% (5/28) are produced in NS0 
cells,3 and 7% (2/28) are produced in 
hybridomas. The remaining two prod-
ucts (ranibizumab, certolizumab pegol) 
are antigen-binding fragments (Fab) that 
are produced in E. coli. Humanized and 
human mAbs comprise 36% (10/28) 
and 32% (9/28) of the total, respec-
tively, while 21% (6/28) are chimeric 
and 11% (3/28) are murine. Most (75%; 
21/28) are canonical full-length mAbs. 
Of the 7 non-canonical mAbs, three 
(abciximab, ranibizumab, certolizumab 
pegol) are Fab, with one of these (cer-
tolizumab pegol) pegylated; two (tosi-
tumomab-I131, ibrituximab tiuxetan) 
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are radiolabeled when administered to 
patients; one (brentuximab vedotin) is an 
antibody-drug conjugate (ADC); and one 
is bispecific (catumaxomab). Although 
16 marketed mAbs target unique anti-
gens, CD20 and tumor necrosis factor 
are each targeted by 4 mAbs, and epider-
mal growth factor receptor (EGFR) and 
vascular endothelial growth factor are 
each targeted by 2 mAbs. If approved, 
pertuzumab, which is undergoing regu-
latory review in Europe and the US as a 
treatment for breast cancer, would be one 
of 2 mAbs that target human epidermal 
growth factor receptor 2 on the market.
In addition to the 28 mAbs currently 
marketed, six mAbs were approved in 
at least one country of Europe or in the 
US, but were subsequently withdrawn or 
discontinued from marketing for vari-
ous reasons (Table 2). First approved in 
the US in 1986, muromonab-CD3 
(Orthoclone OKT3®) was a murine 
IgG2a used to treat acute kidney allograft 
rejection; however, manufacturing was 
discontinued in 2010 due to the availabil-
ity of other treatments with similar effi-
cacy and fewer side effects, and declining 
sales.4,5 Nebacumab (Centoxin®), a 
human IgM, was approved in The 
Netherlands, Britain, Germany and 
France during 1991 as a treatment for 
Gram-negative sepsis,6 but the product 
was subsequently withdrawn for safety, 
efficacy and commercial reasons.7 The 
murine anti-epithelial cell adhesion mol-
ecule (EpCAM) edrecolomab (Panorex®) 
was approved in Germany in 1995 as an 
adjuvant treatment for colon cancer, but 
subsequently withdrawn because of the 
product’s lack of efficacy.8 Daclizumab 
was first approved in 1997 for prophy-
laxis of acute organ rejection in patients 
receiving renal transplants, but the prod-
uct was voluntarily withdrawn from the 
market in Europe effective January 1, 
2009 9 and discontinued for the US mar-
ket because of the availability of alterna-
tive therapy and the diminished market 
demand.10 The first ADC to be approved, 
gemtuzumab ozogamicin was marketed 
in the US for a decade before being vol-
untarily withdrawn in 2010. The prod-
uct was approved under the accelerated 
approval mechanism as a treatment for 
acute myeloid leukemia (AML), but 
was withdrawn when a confirmatory 
clinical trial and post-approval use did 
not show evidence of clinical benefit in 
AML patients.11 Efalizumab (Raptiva®) 
was approved in the US and Europe in 
2003 and 2004, respectively, as a treat-
ment for adults with moderate to severe 
plaque psoriasis, but the product was 
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leukemia-lymphoma and peripheral 
T-cell lymphoma.
The 35 marketed mAbs, most of which 
are canonical full-length IgG1, paved the 
way for the next generation of antibody-
based therapeutics such as ADCs, bispe-
cific antibodies, engineered antibodies 
and antibody fragments or domains. The 
commercial pipeline includes ~350 mAbs 
now being evaluated in clinical studies 
Cuba. The mAb is marketed in over 20 
countries, including Brazil, India and 
China, as a treatment for head and neck 
cancer or glioma, but it is not approved in 
the EU, US or Japan.14 Mogamulizumab 
is a defucosylated humanized anti-
CC chemokine receptor 4 (CCR4) 
antibody developed by Kyowa Hakko 
Kirin Co., Ltd.15 The mAb is approved 
in Japan as a treatment for adult T-cell 
voluntarily withdrawn from both mar-
kets in 2009 because of the risk of side 
effects, including progressive multifocal 
leukoencephalopathy.12,13
The European Union and the US 
are not necessarily the first or only mar-
kets for therapeutic mAbs (Table 3). 
Nimotuzumab, a humanized mAb that 
targets EGFR, was developed at the 
Center of Molecular Immunology in 
Table 1. therapeutic monoclonal antibodies marketed or in review in the European Union or United states
International non-proprietary name (Trade name) Manufacturing cell line Type Target First EU (US) approval year
Abciximab (reopro®) sp2/0 Chimeric igG1κ Fab GPiib/iiia 1995* (1994)
rituximab (Mabthera®, rituxan®) CHo Chimeric igG1κ Cd20 1998 (1997)
Basiliximab (simulect®) sp2/0 Chimeric igG1κ iL2r 1998 (1998)
Palivizumab (synagis®) ns0 Humanized igG1κ rsV 1999 (1998)
infliximab (remicade®) sp2/0 Chimeric igG1κ tnF 1999 (1998)
trastuzumab (Herceptin®) CHo Humanized igG1κ HEr2 2000 (1998)
Alemtuzumab (MabCampath, Campath-1H®) CHo Humanized igG1κ Cd52 2001 (2001)
Adalimumab (Humira®) CHo Human igG1κ tnF 2003 (2002)
tositumomab-i131 (Bexxar®) Hybridoma Murine igG2aλ Cd20 nA (2003)
Cetuximab (Erbitux®) sp2/0 Chimeric igG1κ EGFr 2004 (2004)
ibritumomab tiuxetan (Zevalin®) CHo Murine igG1κ Cd20 2004 (2002)
omalizumab (Xolair®) CHo Humanized igG1κ igE 2005 (2003)
Bevacizumab (Avastin®) CHo Humanized igG1κ VEGF 2005 (2004)
natalizumab (tysabri®) ns0 Humanized igG4κ α4-integrin 2006 (2004)
ranibizumab (Lucentis®) E. coli Humanized igG1κ Fab VEGF 2007 (2006)
Panitumumab (Vectibix®) CHo Human igG2κ EGFr 2007 (2006)
Eculizumab (soliris®) ns0 Humanized igG2/4κ C5 2007 (2007)
Certolizumab pegol (Cimzia®) E. coli
Humanized igG1κ Fab, 
pegylated
tnF 2009 (2008)
Golimumab (simponi®) sp2/0 Human igG1κ tnF 2009 (2009)
Canakinumab (ilaris®) sp2/0 Human igG1κ iL1b 2009 (2009)
Catumaxomab (removab®) Hybrid hybridoma
rat igG2b/mouse igG2a 
bispecific
EpCAM/Cd3 2009 (nA)
Ustekinumab (stelara®) sp2/0 Human igG1κ iL12/23 2009 (2009)
tocilizumab (roActemra, Actemra®) CHo Humanized igG1κ iL6r 2009 (2010)
ofatumumab (Arzerra®) ns0 Human igG1κ Cd20 2010 (2009)
denosumab (Prolia®) CHo Human igG2κ rAnK-L 2010 (2010)
Belimumab (Benlysta®) ns0 Human igG1l BLys 2011 (2011)
raxibacumab (Pending) ns0** Human igG1κ B. anthrasis PA nA (in review)
ipilimumab (Yervoy®) CHo Human igG1κ CtLA-4 2011 (2011)
Brentuximab vedotin (Adcentris®) CHo
Chimeric igG1κ; conjugated 
to monomethyl auristatin E
Cd30 in review (2011)
Pertuzumab (Pending) CHo Humanized igG1κ HEr2 in review (in review)
note: information current as of March 10, 2012. *Country-specific approval; approved under concertation procedure **Product manufactured for 
Phase 1 study in humans. Abbreviations: BLys, B lymphocyte stimulator; C5, complement 5; Cd, cluster of differentiation; CHo, Chinese hamster ovary; 
CtLA-4, cytotoxic t lymphocyte antigen 4; EGFr, epidermal growth factor receptor; EpCAM, epithelial cell adhesion molecule; Fab, antigen-binding 
fragment; GP glycoprotein; iL, interleukin; nA, not approved; PA, protective antigen; rAnK-L, receptor activator of nFκb ligand; rsV, respiratory syncy-
tial virus; tnF, tumor necrosis factor; VEGF, vascular endothelial growth factor. sources: European Medicines Agency public assessment reports, United 
states Food and drug Administration (drugs@fda), the international imMunoGenetics information system® (www.imgt.org/mAb-dB/index).©2 0 1 1   L a n d e s   B i o s c i e n c e .
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around the world as treatments for many 
indications, including cancer, immuno-
logical disorders and infectious diseases.16 
The compendium of marketed therapeu-
tic antibodies may thus be substantially 
larger in the future.
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Table 2. therapeutic monoclonal antibodies withdrawn or discontinued from marketing in the European Union or United states
International proprietary name (Trade name) Manufacturing cell line Type Target First EU (US) approval year
Muromonab-Cd3 (orthoclone oKt3®) Hybridoma Murine igG2a Cd3 1986* (1986)
nebacumab (Centoxin®) Hybridoma Human igM Endotoxin 1991* (nA)
Edrecolomab (Panorex®) Hybridoma Murine igG2a EpCAM 1995* (nA)
daclizumab (Zenapax®) ns0 Humanized igG1κ iL2r 1999 (1997)
Gemtuzumab ozogamicin (Mylotarg®) ns0 Humanized igG4κ Cd33 nA (2000)
Efalizumab (raptiva®) CHo Humanized igG1κ Cd11a 2004 (2003)
note: information current as of March 10, 2012. *European country-specific approval. Abbreviations: Cd, cluster of differentiation; CHo, Chinese 
hamster ovary; EpCAM, epithelial cell adhesion molecule; iL, interleukin; nA, not approved. sources: European Medicines Agency public assessment 
reports, United states Food and drug Administration (drugs@fda), the international imMunoGenetics information system® (www.imgt.org/mAb-dB/
index).
Table 3. therapeutic monoclonal antibodies approved outside the European Union or United states
International proprietary name (Trade name) Manufacturing cell line Type Target First approval year
nimotuzumab (theraCiM®, BioMAB-EGFr®)  ns0 Humanized igG1κ EGFr 1999
Mogamulizumab [not found] Humanized igG1κ CCr4 2012
note: information current as of March 30, 2012. Abbreviations: CCr, chemokine receptor; EGFr, epidermal growth factor receptor.